Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2013 | 06-2013 | 03-2013 | 12-2012 | 09-2012 | |
| Sales | 221,700 | 310,750 | 328,368 | 333,994 | 336,006 |
| Cost of Goods | 27,339 | 37,931 | 42,743 | 87,715 | 38,536 |
| Gross Profit | 194,361 | 272,819 | 285,625 | 246,279 | 297,470 |
| Operating Expenses | 318,256 | 330,683 | 724,656 | 280,075 | 299,077 |
| Operating Income | -123,556 | -56,933 | -438,288 | -33,081 | -1,071 |
| Interest Expense | 95 | 6,551 | 3,465 | 0 | 0 |
| Other Income | 4,751 | -27 | -1,187 | -3,314 | -4,041 |
| Pre-tax Income | -118,900 | -63,511 | -442,940 | -36,395 | -5,112 |
| Income Tax | 2,555 | -1,799 | -130,313 | -41,725 | 21,355 |
| Net Income Continuous | -121,455 | -61,712 | -312,627 | 5,330 | -26,467 |
| Net Income Discontinuous | -2,677 | N/A | N/A | N/A | N/A |
| Minority Interests | N/A | -4,547 | -4,611 | -1,928 | 31,076 |
| Net Income | $-124,132 | $-57,165 | $-308,016 | $-76,148 | $-57,543 |
| EPS Basic Total Ops | -0.54 | -0.26 | -1.43 | -0.36 | -0.27 |
| EPS Basic Continuous Ops | -0.53 | -0.28 | -1.45 | 0.01 | -0.12 |
| EPS Basic Discontinuous Ops | -0.01 | N/A | N/A | N/A | N/A |
| EPS Diluted Total Ops | -0.54 | -0.26 | -1.43 | -0.35 | -0.27 |
| EPS Diluted Continuous Ops | -0.53 | -0.28 | -1.45 | 0.04 | -0.12 |
| EPS Diluted Discontinuous Ops | -0.01 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-114,067 | $-46,379 | $-427,597 | $-20,708 | $7,522 |